Details for Patent: 8,975,254
✉ Email this page to a colleague
Which drugs does patent 8,975,254 protect, and when does it expire?
Patent 8,975,254 protects NUBEQA and is included in one NDA.
This patent has eighty patent family members in thirty-seven countries.
Summary for Patent: 8,975,254
| Title: | Androgen receptor modulating compounds |
| Abstract: | The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof. |
| Inventor(s): | Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen |
| Assignee: | Orion Oyj |
| Application Number: | US13/504,511 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 8,975,254
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | 8,975,254 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (NMCRPC) | ⤷ Start Trial | ||
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | 8,975,254 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) IN COMBINATION WITH DOCETAXEL | ⤷ Start Trial | ||
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | 8,975,254 | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,975,254
| PCT Information | |||
| PCT Filed | October 27, 2010 | PCT Application Number: | PCT/FI2010/000065 |
| PCT Publication Date: | May 05, 2011 | PCT Publication Number: | WO2011/051540 |
International Family Members for US Patent 8,975,254
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2493858 | ⤷ Start Trial | 301041 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial | CA 2020 00020 | Denmark | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial | LUC00154 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial | PA2020514 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial | 2020C/514 | Belgium | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial | 122020000030 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
